Switch theme
Sign up to access all valuation multiples
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
2001
1.8K+
LTM Revenue $2.6B
LTM EBITDA $967M
$10.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sobi has a last 12-month revenue of $2.6B and a last 12-month EBITDA of $967M.
In the most recent fiscal year, Sobi achieved revenue of $2.6B and an EBITDA of $924M.
Sobi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sobi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.2B | $2.6B | XXX | XXX | XXX |
| Gross Profit | $1.4B | $1.7B | XXX | XXX | XXX |
| Gross Margin | 63% | 66% | XXX | XXX | XXX |
| EBITDA | $718M | $924M | XXX | XXX | XXX |
| EBITDA Margin | 33% | 36% | XXX | XXX | XXX |
| Net Profit | $262M | $239M | XXX | XXX | XXX |
| Net Margin | 12% | 9% | XXX | XXX | XXX |
| Net Debt | $735M | $1.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sobi's stock price is SEK 261 (or $26).
Sobi has current market cap of SEK 89.8B (or $8.9B), and EV of SEK 105B (or $10.5B).
See Sobi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.5B | $8.9B | XXX | XXX | XXX | XXX | $1.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sobi has market cap of $8.9B and EV of $10.5B.
Sobi's trades at 4.0x LTM EV/Revenue multiple, and 10.8x LTM EBITDA.
Analysts estimate Sobi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sobi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $10.5B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.3x | XXX | XXX | XXX |
| P/E | 23.1x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 24.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSobi's NTM/LTM revenue growth is 10%
Sobi's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Sobi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sobi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sobi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 45% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sobi acquired XXX companies to date.
Last acquisition by Sobi was XXXXXXXX, XXXXX XXXXX XXXXXX . Sobi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sobi founded? | Sobi was founded in 2001. |
| Where is Sobi headquartered? | Sobi is headquartered in Sweden. |
| How many employees does Sobi have? | As of today, Sobi has 1.8K+ employees. |
| Who is the CEO of Sobi? | Sobi's CEO is Mr. Guido Oelkers. |
| Is Sobi publicy listed? | Yes, Sobi is a public company listed on STO. |
| What is the stock symbol of Sobi? | Sobi trades under SOBI ticker. |
| When did Sobi go public? | Sobi went public in 2006. |
| Who are competitors of Sobi? | Similar companies to Sobi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sobi? | Sobi's current market cap is $8.9B |
| What is the current revenue of Sobi? | Sobi's last 12-month revenue is $2.6B. |
| What is the current EBITDA of Sobi? | Sobi's last 12-month EBITDA is $967M. |
| What is the current EV/Revenue multiple of Sobi? | Current revenue multiple of Sobi is 4.0x. |
| What is the current EV/EBITDA multiple of Sobi? | Current EBITDA multiple of Sobi is 10.8x. |
| What is the current revenue growth of Sobi? | Sobi revenue growth between 2023 and 2024 was 18%. |
| Is Sobi profitable? | Yes, Sobi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
